Venus MedTech-B (02500.HK) Surges Over 10% on Strategic Divestment of 1.05% Equity in DeJin Medical to Sharpen Focus on Core Business

According to the Zhongtong Finance APP, Venus Medtech-B (02500) surged over 10% in the afternoon session. As of press time, it rose 9.8%, trading at HK$3.36, with a turnover of HK$13.7676 million.

On the news front, Kunbo Medical plans to acquire 1.05% equity of Valgen Medtech from Venus Medtech for a total consideration of 15 million US dollars. Venus Medtech stated that as a minority financial investor of the invested company, the sale represents an appropriate opportunity for the Group to realize its investment. By divesting non-core business investments, the Group will be able to strengthen its cash flow, improve its working capital position, enhance overall financial flexibility, and facilitate the reallocation of resources to its core business.

Notably, Venus Medtech recently announced that the group has officially submitted all application materials for the CE MDR certification of its Cardiovalve Transcatheter Tricuspid Valve Replacement System to the European Notified Body. This marks a critical step forward in the product’s market entry process in Europe and signifies that Venus Medtech is further enhancing its tricuspid valve treatment portfolio, building on its already well-established aortic and pulmonary valve product lines.